Showing 1971-1980 of 2652 results for "".
- Trial Highlights 5-Year Performance of 2 Standalone Glaukos iStents vs. Topical Prostaglandinhttps://modernod.com/news/trial-highlights-5-year-performance-of-2-standalone-glaukos-istents-vs-topical-prostaglandin/2476466/Glaukos announced that results of an international glaucoma study published in Ophthalmology Glaucoma showed standalone implantation of two iStent Trabecular Micro-Bypass Stents in newly diagnosed primary open-angle glaucoma (POAG) eyes achieved a 35.3% reduction in mean IOP to 16.5 mmHg
- Study: Glaukos iStent inject Implantation with Concomitant Cataract Surgery Provides Sustained Reduction in IOP and Medication Burdenhttps://modernod.com/news/study-glaukos-istent-inject-implantation-with-concomitant-cataract-surgery-provides-sustained-reduction-in-iop-and-medication-burden/2479620/Glaukos announced that a single-site international study of glaucoma subjects recently published in Ophthalmology and Therapy showed that the iStent inject Trabecular Micro-Bypass System, combined with cataract surgery, achieved a 37% reduction in mean IOP to 14.3 mmHg after 3 years of f
- SECO International Partners With the American Society of Optometric Surgeons for SECO 2019https://modernod.com/news/seco-international-partners-with-the-american-society-of-optometric-surgeons-for-seco-2019/2479621/SECO International has announced that SECO, the educational conference providing ophthalmic professionals educational opportunities since 1924, has partnered with the American Society of Optometric Surgeons (ASOS) to bring hands-on demonstrations showing radiosurgical technology, Botox, and YAG l
- Envision Conference to Split in Two in 2019https://modernod.com/news/envision-conference-to-split-in-two-in-2019/2479634/For the first time since its inception in 2006, Envision Conference will be split into two events for the upcoming year: Envision Conference East, March 22-23, 2019 at the University of Alabama at Birmingham in Birmingham, Alabama; and Envision Conference West, October 5-6, 2019 at the College of
- Flying Eye Hospital Celebrates 20 Years of Eye Care in Ethiopia this World Sight Dayhttps://modernod.com/news/flying-eye-hospital-celebrates-20-years-of-eye-care-in-ethiopia-this-world-sight-day/2479789/The Orbis Flying Eye Hospital—the world’s only U.S.-accredited teaching hospital on board an MD-10 aircraft—has returned to Addis Ababa to conduct a 3-week training project from October 1-19, 2018, invited by the Federal Ministr
- “Dr. Robert Ritch Forum on Medicine of the Future” at World Ophthalmology Congress 2018https://modernod.com/news/dr-robert-ritch-forum-on-medicine-of-the-future-at-world-ophthalmology-congress-2018/2480090/Robert Ritch, MD, Distinguished Chair in Ophthalmology at New York Eye and Ear Infirmary of Mount Sinai will host the “Robert Ritch Forum on Medicine of the Future” at the World Ophthalmology Congress 2018 (WOC2018) in Barcelona, Spain. This is the first time WOC is dedicating an entire fo
- New Study Suggests Indoor Visual Habits May Be Driving Myopia Surgehttps://modernod.com/news/new-study-suggests-indoor-visual-habits-may-be-driving-myopia-surge/2485803/For years, the global rise in myopia has largely been blamed on increased screen time, particularly among children and young adults. But new research from scientists at the SUNY College of Optometry suggests the explanation may be more nuanced—and rooted in a common
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen
- BostonSight Announces Leadership Changes to Advance Ocular Surface Care Worldwidehttps://modernod.com/news/bostonsight-announces-leadership-changes-to-advance-ocular-surface-care-worldwide/2485722/BostonSight announced a 5-year strategic roadmap designed to redefine ocular surface treatment through advancements in clinical research, professional education, and specialty lens technology. As part of the plan, BostonSight announced a new leadership structure ai
- HOYA Presents New Data on MiYOSMART iQ Spectacle Lenseshttps://modernod.com/news/hoya-presents-new-data-on-miyosmart-iq-spectacle-lenses/2485625/HOYA Vision Care recently announced interim 6-month data from its randomized controlled clinical trial evaluating the safety and efficacy of MiYOSMART iQ spectacle lenses to treat children 4 to 12 years of age who have progressive myopia. The company’s myopia control solution uses the defocu